KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Income from Continuing Operations (2016 - 2025)

Inovio Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 20658347.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 21.27% year-over-year to 20658347.0; the TTM value through Sep 2025 reached 86891654.0, up 23.31%, while the annual FY2024 figure was 107809762.0, 20.21% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 20658347.0 at Inovio Pharmaceuticals, up from 22473881.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 19516974.0 in Q4 2024 and bottomed at 108497311.0 in Q2 2022.
  • The 5-year median for Income from Continuing Operations is 35534533.0 (2023), against an average of 46904156.26.
  • The largest annual shift saw Income from Continuing Operations crashed 387.46% in 2021 before it skyrocketed 67.25% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 106947580.0 in 2021, then soared by 49.07% to 54463139.0 in 2022, then soared by 54.09% to 25003638.0 in 2023, then grew by 21.94% to 19516974.0 in 2024, then dropped by 5.85% to 20658347.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Income from Continuing Operations are 20658347.0 (Q3 2025), 22473881.0 (Q2 2025), and 24242452.0 (Q1 2025).